India recorded 44983152 Coronavirus Cases since the epidemic began, according to the World Health Organization (WHO). In addition, India reported 531794 Coronavirus Deaths. This dataset includes a chart with historical data for India Coronavirus Cases.

This dataset provides values for CORONAVIRUS DEATHS reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

The Indian state of Punjab reported the highest number of active coronavirus (COVID-19) cases of over one thousand cases as of October 20, 2023. Kerala and Karnataka followed, with relatively lower casualties. That day, there were a total of over 44 million confirmed infections across India.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team, except for aggregation of individual case count data into daily counts when that was the best data available for a disease and location. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretability. We also formatted the data into a standard data format. All geographic locations at the country and admin1 level have been represented at the same geographic level as in the data source, provided an ISO code or codes could be identified, unless the data source specifies that the location is listed at an inaccurate geographical level. For more information about decisions made by the curation team, recommended data processing steps, and the data sources used, please see the README that is included in the dataset download ZIP file.

India reported over 44 million confirmed cases of the coronavirus (COVID-19) as of October 20, 2023. The number of people infected with the virus was declining across the south Asian country.

What is the coronavirus?

COVID-19 is part of a large family of coronaviruses (CoV) that are transmitted from animals to people. The name COVID-19 is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged. Symptoms of COVID-19 resemble that of the common cold, with fever, coughing, and shortness of breath. However, serious infections can lead to pneumonia, multi-organ failure, severe acute respiratory syndrome, and even death, if appropriate medical help is not provided.

COVID-19 in India

India reported its first case of this coronavirus in late January 2020 in the southern state of Kerala. That led to a nation-wide lockdown between March and June that year to curb numbers from rising. After marginal success, the economy opened up leading to some recovery for the rest of 2020. In March 2021, however, the second wave hit the country causing record-breaking numbers of infections and deaths, crushing the healthcare system. The central government has been criticized for not taking action this time around, with "#ResignModi" trending on social media platforms in late April. The government's response was to block this line of content on the basis of fighting misinformation and reducing panic across the country.

Context This is the covid-19 dataset of confirmed cases and deaths from 06-05-2021.

Acknowledgments Thank you Johns Hopkins University for providing the data every day.

Inspiration I thought it will be helpful for the Kaggle community to work on the dataset.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

Context

• A new coronavirus designated 2019-nCoV was first identified in Wuhan, the capital of China's Hubei province
• People developed pneumonia without a clear cause and for which existing vaccines or treatments were not effective.
• The virus has shown evidence of human-to-human transmission
• Transmission rate (rate of infection) appeared to escalate in mid-January 2020
• As of 16 March 2020, approximately 170,237 cases have been confirmed
• In India, 110 cases have been confirmed until 15th March, 2020.

Content

Each row represent the daily confirmed cases in India.

Acknowledgements

Ministry of Health and Family Welfare.

Inspiration

To create awareness among Indians regarding the spread of Covid-19.

Content

The WHO coronavirus (COVID-19) dashboard presents official daily counts of COVID-19 cases, deaths and vaccine utilization reported by countries, territories and areas. Through this dashboard, we aim to provide a frequently updated data visualization, data dissemination and data exploration resource, while linking users to other useful and informative resources.

Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, vaccination strategy, and reporting strategies.

Acknowledgements

© World Health Organization 2020, All rights reserved.

WHO supports open access to the published output of its activities as a fundamental part of its mission and a public benefit to be encouraged wherever possible. Permission from WHO is not required for the use of the WHO coronavirus disease (COVID-19) dashboard material or data available for download. It is important to note that:

WHO publications cannot be used to promote or endorse products, services or any specific organization.

WHO logo cannot be used without written authorization from WHO.

WHO provides no warranty of any kind, either expressed or implied. In no event shall WHO be liable for damages arising from the use of WHO publications.

For further information, please visit WHO Copyright, Licencing and Permissions.

Citation: WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https://covid19.who.int/

Inspiration

Daily cases start increasing suddenly just before the new year and there's a fear for the upcoming wave. Everybody starts to predict the peak cases in the 3rd wave and the date the peak will be reached. Assume you are in the 1st week of January 2022 and there's panic in the country, for the Omicron variant is said to be highly transmittable. Using your machine learning and deep learning skills, you have to create a model that predicts accurately the peak for the 3rd wave.

IntroductionRecent reviews summarize evidence that some vaccines have heterologous or non-specific effects (NSE), potentially offering protection against multiple pathogens. Numerous economic evaluations examine vaccines' pathogen-specific effects, but less than a handful focus on NSE. This paper addresses that gap by reporting economic evaluations of the NSE of oral polio vaccine (OPV) against under-five mortality and COVID-19.Materials and methodsWe studied two settings: (1) reducing child mortality in a high-mortality setting (Guinea-Bissau) and (2) preventing COVID-19 in India. In the former, the intervention involves three annual campaigns in which children receive OPV incremental to routine immunization. In the latter, a susceptible-exposed-infectious-recovered model was developed to estimate the population benefits of two scenarios, in which OPV would be co-administered alongside COVID-19 vaccines. Incremental cost-effectiveness and benefit-cost ratios were modeled for ranges of intervention effectiveness estimates to supplement the headline numbers and account for heterogeneity and uncertainty.ResultsFor child mortality, headline cost-effectiveness was $650 per child death averted. For COVID-19, assuming OPV had 20% effectiveness, incremental cost per death averted was $23,000–65,000 if it were administered simultaneously with a COVID-19 vaccine

Coronavirus disease 2019 (COVID-19)

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in 2019 in Wuhan, China, and has since spread globally, resulting in the 2019–20 coronavirus pandemic. Epidemiologists are teaming up with data scientists to stem the spread of the novel coronavirus by tapping big data, machine learning and other digital tools. The goal is to get real-time forecasts and other critical information to front-line health-care workers and public policy makers as the outbreak unfolds. The objective of the Hackathon is to predict the probability of person getting infected by Covid-19.

Coronaviruses are a family of hundreds of viruses that can cause fever, respiratory problems, and sometimes gastrointestinal symptoms too. The 2019 novel coronavirus is one of seven members of this family known to infect humans, and the third in the past three decades to jump from animals to humans. Since emerging in China in December, this new coronavirus has caused a global health emergency, sickening almost 200,000 people worldwide, and so far killing more than 9,000. As of March 19, about 10000 cases had been reported in the US, and 155 people have died. In Wuhan, home to 11 million people, the initial number of cases was 40, estimated by a group of researchers led by Natsuko Imai of Imperial College. The number of exposed was assumed to be 20 times this number. The basic reproduction number (BRN) is the expected number of cases directly generated by one case. A BRN greater than one indicates that the outbreak is self-sustaining, while a BRN less than one indicates that the number of new cases decreases over time and eventually the outbreak will stop. Ideally, the BRN should be reduced in order to slow down an epidemic. The BRN in the first three phases was estimated to be 3.1, 2.6, and 1.9, respectively. In the Cell Discovery article, the BRN is assumed to have decreased to 0.9 or 0.5 in phase IV, based on previous experience in SARS. According to an article in Science in 2003, the BRN of SARS decreased from 2.7 to 0.25 after the patients were isolated and the infection started being controlled. The better we can track the virus, the better we can fight it. By analyzing different parameters responsible for the outbreak of coronavirus, we can take controlling measures in an accelerated way.

Part -01 :

The objective of the first part of the problem statement is to predict the probability of a person getting infected by Covid-19 on 20 th March 2020. The output file 01 should contain only people_ID and the respective infect_prob for the test data.

Part -02 :

The Diuresis of a person is a time-dependent parameter, for which you have to come up with a Time-series prediction model. Using the Diuresis predicted by the model, you need to calculate the infect_prob on 27 th March 2020 for every people_ID in the test data. . The output file 02 should contain only people_ID and the respective infect_prob on 27 th March.

This dataset corresponds to paper titled "A Mathematical Model for COVID-19 Considering Waning Immunity, Vaccination and Control Measures". In this work we define a modified SEIR model that accounts for the spread of infection during the latent period, infections from asymptomatic or pauci-symptomatic infected individuals, potential loss of acquired immunity, people’s increasing awareness of social distancing and the use of vaccination as well as non-pharmaceutical interventions like social confinement. We estimate model parameters in three different scenarios - in Italy, where there is a growing number of cases and re-emergence of the epidemic, in India, where there are significant number of cases post confinement period and in Victoria, Australia where a re-emergence has been controlled with severe social confinement program. Our result shows the benefit of long term confinement of 50% or above population and extensive testing. With respect to loss of acquired immunity, our model suggests higher impact for Italy. We also show that a reasonably effective vaccine with mass vaccination program can be successful in significantly controlling the size of infected population. We show that for India, a reduction in contact rate by 50% compared to a reduction of 10% in the current stage can reduce death from 0.0268% to 0.0141% of population. Similarly, for Italy we show that reducing contact rate by half can reduce a potential peak infection of 15% population to less than 1.5% of population, and potential deaths from 0.48% to 0.04%. With respect to vaccination, we show that even a 75% efficient vaccine administered to 50% population can reduce the peak number of infected population by nearly 50% in Italy. Similarly, for India, a 0.056% of population would die without vaccination, while 93.75% efficient vaccine given to 30\% population would bring this down to 0.036% of population, and 93.75% efficient vaccine given to 70% population would bring this down to 0.034%.

Tuberculosis (TB) is the leading infectious disease cause of death worldwide. In recent years, stringent measures to contain the spread of SARS-CoV-2 have led to considerable disruptions of healthcare services for TB in many countries. The extent to which these measures have affected TB testing, treatment initiation and outcomes has not been comprehensively assessed. We aimed to estimate TB healthcare service disruptions occurring during the COVID-19 pandemic in Brazil, India, and South Africa. We obtained country-level TB programme and laboratory data and used autoregressive integrated moving average (ARIMA) time-series models to estimate healthcare service disruptions with respect to TB testing, treatment initiation, and treatment outcomes. We quantified disruptions as the percentage difference between TB indicator data observed during the COVID-19 pandemic compared with values for a hypothetical no-COVID scenario, predicted through forecasting of trends during a three-year pre-pandemic period. Annual estimates for 2020–2022 were derived from aggregated monthly data. We estimated that in 2020, the number of bacteriological tests conducted for TB diagnosis was 24.3% (95% uncertainty interval: 8.4%;36.6%) lower in Brazil, 27.8% (19.8;3 4.8%) lower in India, and 32.0% (28.9%;34.9%) lower in South Africa compared with values predicted for the no-COVID scenario. TB treatment initiations were 17.4% (13.9%;20.6%) lower than predicted in Brazil, 43.3% (39.8%;46.4%) in India, and 27.0% (15.2%;36.3%) in South Africa. Reductions in 2021 were less severe compared with 2020. The percentage deaths during TB treatment were 13.7% (8.1%; 19.7%) higher than predicted in Brazil, 1.7% (-8.9%;14.0%) in India and 21.8% (7.4%;39.2%) in South Africa. Our analysis suggests considerable disruptions of TB healthcare services occurred during the early phase of the COVID-19 pandemic in Brazil, India, and South Africa, with at least partial recovery in the following years. Sustained efforts to mitigate the detrimental impact of COVID-19 on TB healthcare services are needed.

Humanity has seen numerous pandemics during its course of evolution. The list includes several incidents from the past, such as measles, Ebola, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), etc. The latest edition to this is coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of August 18, 2020, COVID-19 has affected over 21 million people from 180 + countries with 0.7 million deaths across the globe. Genomic technologies have enabled us to understand the genomic constitution of pathogens, their virulence, evolution, and rate of mutation, etc. To date, more than 83,000 viral genomes have been deposited in public repositories, such as GISAID and NCBI. While we are writing this, India is the third most affected country by COVID-19, with 2.7 million cases and > 53,000 deaths. Gujarat is the 11th highest affected state with a 3.48% death rate compared to the national average of 1.91%. In this study, a total of 502 SARS-CoV-2 genomes from Gujarat were sequenced and analyzed to understand its phylogenetic distribution and variants against global and national sequences. Further variants were analyzed from diseased and recovered patients from Gujarat and the world to understand its role in pathogenesis. Among the missense mutations present in the Gujarat SARS-CoV-2 genomes, C28854T (Ser194Leu) had an allele frequency of 47.62 and 7.25% in deceased patients from the Gujarat and global datasets, respectively. In contrast, the allele frequency of 35.16 and 3.20% was observed in recovered patients from the Gujarat and global datasets, respectively. It is a deleterious mutation present in the nucleocapsid (N) gene and is significantly associated with mortality in Gujarat patients with a p-value of 0.067 and in the global dataset with a p-value of 0.000924. The other deleterious variant identified in deceased patients from Gujarat (p-value of 0.355) and the world (p-value of 2.43E-06) is G25563T, which is located in Orf3a and plays a potential role in viral pathogenesis. SARS-CoV-2 genomes from Gujarat are forming distinct clusters under the GH clade of GISAID. This study will shed light on the viral haplotype in SARS-CoV-2 samples from Gujarat, India.

This dataset corresponds to paper titled "COVID-19: Risks of Re-emergence, Re-infection, and Control Measures -- A Long Term Modeling Study". In this work we define a modified SEIR model that accounts for the spread of infection during the latent period, infections from asymptomatic or pauci-symptomatic infected individuals, potential loss of acquired immunity, people’s increasing awareness of social distancing and the use of vaccination as well as non-pharmaceutical interventions like social confinement. We estimate model parameters in three different scenarios - in Italy, where there is a growing number of cases and re-emergence of the epidemic, in India, where there are significant number of cases post confinement period and in Victoria, Australia where a re-emergence has been controlled with severe social confinement program. Our result shows the benefit of long term confinement of 50% or above population and extensive testing. With respect to loss of acquired immunity, our model suggests higher impact for Italy. We also show that a reasonably effective vaccine with mass vaccination program can be successful in significantly controlling the size of infected population. We show that for India, a reduction in contact rate by 50% compared to a reduction of 10% in the current stage can reduce death from 0.0268% to 0.0141% of population. Similarly, for Italy we show that reducing contact rate by half can reduce a potential peak infection of 15% population to less than 1.5% of population, and potential deaths from 0.48% to 0.04%. With respect to vaccination, we show that even a 75% efficient vaccine administered to 50% population can reduce the peak number of infected population by nearly 50% in Italy. Similarly, for India, a 0.056% of population would die without vaccination, while 93.75% efficient vaccine given to 30\% population would bring this down to 0.036% of population, and 93.75% efficient vaccine given to 70% population would bring this down to 0.034%.